| (Values in U.S. Thousands) | Sep, 2025 | Sep, 2024 | Sep, 2023 | Sep, 2022 | Sep, 2021 |
| Sales | 37,920 | 25,100 | 46,470 | 64,860 | 57,100 |
| Sales Growth | +51.08% | -45.99% | -28.35% | +13.59% | +14.13% |
| Net Income | -19,940 | -1,440 | -7,780 | 1,080 | 3,150 |
| Net Income Growth | -1,284.72% | +81.49% | -820.37% | -65.71% | -37.75% |
Bgm Group Ltd (BGM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
BGM Group Ltd. is a company dedicated to the fields of biopharmaceuticals, bio-extraction and medical health. Its current product range includes oxytetracycline APIs, licorice preparations and crude heparin sodium. BGM Group Ltd., formerly known as Qilian International Holding Group Ltd., is headquartered in Chengdu, China.
Fiscal Year End Date: 09/30